

1 **Same-Day Simultaneous Diagnosis of Bacterial and Fungal Infections in Clinical**  
2 **Practice by Nanopore Targeted Sequencing**

3

4 **Running Title:** Pathogens diagnosis by Nanopore Targeted Sequencing

5

6 Ming Wang, MD <sup>#1</sup>; Aisi Fu, MS<sup>#2</sup>; Ben Hu, Ph. D.<sup>2</sup>; Gaigai Shen, BS<sup>2</sup>; Ran Liu, MS<sup>2</sup>;

7 Wanxu Zhao, BS<sup>2</sup>; Shupeng Jiang, MS<sup>1</sup>; Xuan Cai, MD<sup>1</sup>; Congrong Li, MD<sup>1</sup>; Juan Li, MD<sup>1</sup>;

8 Qing Wu, MD<sup>1</sup>; Kai Feng, MS<sup>1</sup>; Jiashuang Gu, BS<sup>3</sup>; Jia Chen, MS<sup>2</sup>; Mingyue Shu, MS<sup>2</sup>;

9 Binghong Zhang, MD<sup>4</sup>; Zixin Deng, Ph. D.<sup>2,5,6</sup>; Lilei Yu, MD<sup>7</sup>; Yan Li, MD<sup>1\*</sup>; Tiangang Liu,

10 Ph. D.<sup>2,6\*</sup>

11 <sup>1</sup> Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, 430060,

12 China

13 <sup>2</sup> Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education

14 and Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, China

15 <sup>3</sup> Wuhan Dgensee Clinical Laboratory Co., Ltd. Wuhan 430075, China

16 <sup>4</sup> Department of Pediatrics, Renmin Hospital of Wuhan University, Wuhan, 430060, China

17 <sup>5</sup> State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of

18 Metabolic & Developmental Sciences, and School of Life Sciences and Biotechnology,

19 Shanghai Jiao Tong University, Shanghai, 200030, China

20 <sup>6</sup> Hubei Engineering Laboratory for Synthetic Microbiology, Wuhan Institute of

21 Biotechnology, Wuhan, 430075, China

22 <sup>7</sup> Department of Internal Medicine, Renmin Hospital of Wuhan University, Wuhan, 430060,

23 China

24 # These authors contributed equally to this work.

25

26 **Corresponding author:**

27 **Prof. Tiangang Liu.** Key Laboratory of Combinatorial Biosynthesis and Drug Discovery,  
28 Ministry of Education and Wuhan University School of Pharmaceutical Sciences, Wuhan  
29 430071, China. Email: liutg@whu.edu.cn. Tel: +86-27-68755086

30 **Prof. Yan Li.** Department of Clinical Laboratory, Renmin Hospital of Wuhan University,  
31 Wuhan, 430060, China Email: yanlitf1120@163.com. Tel: +86-27-88071553

32

33 **Abbreviations:** NTS, nanopore targeted sequencing; ITS1/2, fungal internal transcribed  
34 spacers 1 and 2; ATCC, the American Type Culture Collection; MTB, *Mycobacterium*  
35 *tuberculosis*; BALF, bronchoalveolar lavage fluid; CFU, colony-forming units; RPM, aligned  
36 reads of per million sequence reads; CSF, cerebrospinal fluid; NTM, *Nontuberculous*  
37 *mycobacteria*; PPV, positive predicted value; NPV, negative predicted values; OP,  
38 opportunistic pathogens; CO, commensal bacteria/fungi

39

#### 40 **Keywords**

41 nanopore sequencing, targeted amplification, pathogens diagnose, bacterial infection, fungal  
42 infection

43

#### 44 **Abstract**

45 **BACKGROUND:** As approximately 19% of global deaths are attributable to infectious  
46 diseases, early diagnosis of infection is very important to reduce mortality. Traditional  
47 infection detection strategies have limited sensitivity, detection range, and turnaround times; a  
48 detection technology that can simultaneously detect bacterial and fungal infections within 24  
49 h is urgently need in clinical settings.

50

51 **METHODS:** We developed nanopore targeted sequencing (NTS) for same-day simultaneous

52 diagnosis of fungal and bacterial infections. NTS was developed by amplification of 16s  
53 rRNA gene (for bacteria), IST1/2 gene (for fungal), and *rpoB* (for *Mycobacterium* spp.) using  
54 multiple primers, and sequenced by a real-time nanopore sequencing platform. An in-house  
55 bioinformatic analyze pipeline was used to diagnose the infectious pathogens by mapping the  
56 sequencing results with the constructed databases.

57

58 **RESULTS:** Comparison of 1312 specimens from 1257 patients using NTS and culture  
59 method; NTS detected pathogens in 58.71% of specimens from patients, compared to 22.09%  
60 detected using the culture method. NTS showed significantly higher sensitivity than culture  
61 methods for many pathogens. Importantly, a turnaround time of <24 h for all specimens, and a  
62 pre-report within 6 h in emergency cases was possible in clinical practice. Modification of  
63 antibiotic therapy and maintenance of original anti-infection regimens in 51.52% (17/33) and  
64 36.36% (12/33) of patients was in accordance with NTS results, and quantitative monitoring  
65 of clinical treatment effects was evaluated in four patients by continuous NTS tests.

66

67 **CONCLUSIONS:** Application of NTS in clinically detected pathogens can improve targeted  
68 antibiotic treatment and therapeutic monitoring.

69

## 70 **Introduction**

71 Approximately 19% of global deaths are attributable to infectious diseases, and early  
72 empirical treatment may not improve survival rates or other outcomes (1). The low sensitivity  
73 or biased detection range of individual techniques results in the combined use of pathogen  
74 screening techniques, which will lead to repeated sampling, increased treatment costs, and  
75 extended diagnosis time (2-4). Furthermore, the need for rapid pathogen identification, a wide  
76 pathogen spectrum (3), limited specimen volumes (5), or even asymptomatic infections (6)

77 should be considered.

78 Enormous progress has been made in the development and deployment of sequencing-based  
79 diagnostic methods (4, 7-10). Sequencing-based diagnostic methods have broad detection  
80 ranges and high resolution, particularly for fungal pathogens. However, unbiased  
81 metagenomic methods typically require deep sequencing and extensive bioinformatics  
82 processing to account for host genome dominance, resulting in low-throughput, high costs,  
83 long turnaround times, and low sensitivity (4, 11). Targeted sequence detection requires less  
84 sequencing data and bioinformatics resource, which in theory, can reduce the cost and  
85 turnaround time, therefore suitable for clinical applications. However, due to the short-read  
86 lengths of previous sequencing platforms, its discrimination of pathogens is limited by  
87 incompletely sequenced marker genes, such as the V4-5 region of 16s rRNA gene. The  
88 detection range was also restricted to only bacteria or fungi in a single test due to their  
89 different sized marker genes which cannot be constructed in same sequencing library (8, 12).

90 DNA is sequenced by massively parallel sequencing platforms by detecting optical or  
91 chemical signals. This method accumulates systematic errors generated by sequencing as the  
92 sequencing length increases, limiting the length of sequencing reads (13, 14). Illumina's (the  
93 most widely used massive parallel sequencing platform) sequencing by synthesis approach  
94 requires multiple sequencing cycles, and each cycle takes several minutes to analyze one base  
95 of each DNA fragment. Hence, the sequencing process usually takes 0.5 to 3 days according  
96 to the read length and data output requirement. More importantly, the sequencing data cannot  
97 be used for following analysis until the entire sequencing process is completed. Nanopore  
98 sequencing platform's approach directly detects changes in the generated current when DNA /  
99 RNA molecules pass through a nanopore protein at approximately 300 bp/s, which now  
100 achieving >95% raw read accuracy (15). This electrical signal can be recorded in real-time

101 and used for subsequent sequence analysis immediately (16). In addition, the nanopore  
102 protein does not selectively sequence DNA / RNA with specific lengths. DNA / RNA of  
103 different lengths can pass through the nanopore protein completely, and the length of each  
104 sequencing data is equal to that of the length of the DNA / RNA (17). Therefore, unlike  
105 previous sequencing platforms, the length of nucleic acids in the same sequencing library is  
106 not required to be of a specific range, such as 280-320 bp; all nucleic acids with different  
107 length can be pooled together and sequenced from end to end in a nanopore sequencing  
108 library (18, 19).

109 Real-time data output, end to end sequencing and small size make nanopore sequencing  
110 promising for clinical applications. Previous studies focused on bacterial respiratory infection  
111 using nanopore metagenome sequencing (20-22), however the clinical application was  
112 impeded by relative high costs and extensive bioinformatics processing. Nanopore targeted  
113 sequencing (NTS), which amplified marker genes and used nanopore sequencing platform to  
114 sequence the amplified marker genes, were developed for investigation of bacterial or fungal  
115 infection. However, previous NTS was only based on a single marker gene, such as the 16s  
116 rRNA gene targeted sequencing that has been reported to identify bacterial infection in  
117 individual clinical case reports (23, 24), and fungal ribosomal operon (18S-ITS1-5.8S-ITS2-  
118 28S) has been used to detect the fungal community associated with external otitis in dogs (25).  
119 Simultaneous broad-spectrum detections of bacteria and fungi, and high-sensitivity detection  
120 of critical clinical pathogens in clinical samples by a single test based on NTS have not been  
121 developed. In addition, the performance of the NTS method with a large cohort and  
122 systematic comparisons with classic culture methods have not been examined. Furthermore,  
123 the turnaround time in clinical practice and clinical management applications are unknown.

124 Here, we developed a test based on NTS for the broad-spectrum screening of both bacterial  
125 and fungal pathogens in various clinical specimen types. The diagnostic accuracy and

126 turnaround time of NTS were investigated by comparison with the culture method for 1312  
127 clinical specimens from 1257 patients.

128

## 129 **Materials and Methods**

### 130 SPECIMENS AND CLINICAL ELECTRONIC RECORD

131 The study population consisted of 1312 specimens from 1257 patients at Renmin Hospital of  
132 Wuhan University, China, whose specimens were sent for pathogen testing between  
133 November 2018 and November 2019. Parallel testing by routine culture and NTS was  
134 performed. Adequate material was submitted for culture, and surplus material was processed  
135 by NTS. All specimens (n = 1312) were used to assess the NTS and culture results. The  
136 clinical records of each patient were retrieved and 1005 patients were diagnosed or suspected  
137 with infection by clinicians according to clinical symptoms and/or positive results of other  
138 clinical tests. These patients were used to evaluate the diagnostic yield and sensitivity of NTS.  
139 Patient clinical diagnosis and demographic characteristics were obtained from electronic  
140 medical records (26). The study was approved by the Ethics Committee of Renmin Hospital  
141 of Wuhan University (WDRY2019-K056).

### 142 NTS

143 All primers used in this study are listed in [Table S1](#), the DNA extraction method of specimen  
144 was described in [supporting method](#). Amplification of the 16s rRNA gene and *rpoB* was  
145 performed in a 20  $\mu$ L reaction system with 8  $\mu$ L extracted DNA, 2  $\mu$ L barcoded primer (10  
146  $\mu$ M), and 10  $\mu$ L 2 $\times$ KOD One<sup>TM</sup> PCR Master Mix (TOYOBO) using the following  
147 procedure: 1 cycle at 98 $^{\circ}$ C for 3 min and 35 cycles at 98 $^{\circ}$ C for 10 s, 55 $^{\circ}$ C for 5 s, and 68 $^{\circ}$ C  
148 for 10 s, followed by a final elongation step at 68 $^{\circ}$ C for 5 min. ITS1/2 (fungal internal

149 transcribed spacers 1 and 2, abbreviated as ITS1/2) was first amplified using the same  
150 reaction system and PCR procedure using the primer mix without barcode and the PCR  
151 product was purified with 0.8× AMPure beads (Beckman Coulter) and eluted in 10 µL Tris-  
152 EDTA (TE) buffer. Then, 5 µL eluate was used for barcoding PCR with 5 µL barcoded  
153 ITS1/2 primer set (10 µM) and 10 µL 2× Phusion U Multiplex PCR Master Mix using the  
154 following procedure: 1 cycle at 98°C for 3 min and 10 cycles at 98°C for 10 s, 55°C for 5 s,  
155 and 68°C for 5 s, followed by a final elongation step at 68°C for 5 min. The barcoded  
156 products of the 16s rRNA gene, ITS1/2 and *rpoB* amplification from the same samples were  
157 pooled according to mass ratio of 10:3:1. The pooled products from the different samples  
158 were mixed equally and used to construct sequencing libraries using the 1D Ligation Kit  
159 (SQK-LSK109; Oxford Nanopore). The library was sequenced using Oxford Nanopore  
160 MinION or GridION. TE buffer was assayed in each batch as a negative control. The  
161 bioinformatic analysis was described in the supplement methods section, several  
162 modifications were made following previous studies and samples were tested positive for  
163 bacteria or fungi if they met any of the established thresholds ([Supporting method](#)). Detected  
164 microorganisms were described as critical pathogens, opportunistic pathogens, or typically  
165 nonpathogenic commensal microbes according to published literature and clinical guidelines  
166 (27) ([Table S2](#)).

#### 167 MOCK COMMUNITY

168 All 50 clinical strains used to evaluate performance were isolated from clinical specimens in  
169 the laboratory or purchased from the American Type Culture Collection (ATCC) (Manassas,  
170 VA, USA). Six strains were selected to construct a mock community ([Table S3](#)) and blood  
171 samples were collected from healthy volunteers with no symptoms of infection in physical  
172 examination. The concentration of each strain was determined by calibration curves from  
173 cultures.

## 174 STATISTICAL ANALYSIS

175 The sensitivity, specificity, positive predictive value (PPV), and negative predictive value  
176 (NPV) were calculated as previously described by comparing the NTS results with composite  
177 final clinical diagnosis (28). A P-value < 0.05 was considered significant. Proportional  
178 outcomes were compared using the  $\chi^2$  test or Fisher's exact test. Continuous variables were  
179 compared using the Student's *t*-test or Wilcoxon signed-rank test. Data analyses were  
180 performed using SPSS 22.0.

181

## 182 **Results**

### 183 DESIGN OF NTS FOR SAME-DAY SIMULTANEOUS DIAGNOSIS OF BACTERIAL 184 AND FUNGAL INFECTIONS

185 Full-length bacterial 16s rRNA gene and fungal ITS1/2 gene were selected as universal  
186 marker genes for identification of bacteria and fungi, respectively. For specific markers, as  
187 *Mycobacterium tuberculosis* (MTB) was the most concerned clinical critical pathogen, we  
188 chose *rpoB* for *Mycobacterium* spp. (29) as the target. The design of NTS primers (Table S1)  
189 and the sequencing library preparation were described in the [supporting result](#). For sequencing,  
190 we chose a nanopore platform that could sequence long nucleic acid fragments and  
191 simultaneously analyze the data-output in real-time. This allowed immediate detection of  
192 bacterial and fungal infection by periodical analysis of output sequences using our in-house  
193 bioinformatic pipeline ([supporting methods](#)). In summary, a NTS detection that targeted the  
194 amplification of bacterial and fungal marker genes and that is able to execute nanopore  
195 sequencing to identify the pathogens was developed ([Fig. 1](#)).

196



197 PERFORMANCE OF NTS BASED ON STANDARD STRAINS AND MOCK  
198 COMMUNITIES

199 To verify the identification accuracy, NTS was tested by individual analyses of 50 common  
200 clinical strains isolated from clinical specimens in the laboratory or purchased from ATCC. In  
201 total, 100% and 92% of the tested isolates were identified correctly at the genus and species  
202 level, respectively (Table S4). Considering clinical samples, such as sputum, that usually  
203 contain high abundance of commensal microbes and that the pathogens may have relatively  
204 lower abundance, in order to investigate the sensitivity and sequencing data required for  
205 detection the low-abundance microbes, a mock community (three bacteria and three fungi)  
206 was constructed to simulate a complex clinical sample and the concentration of each strain  
207 was determined by calibration curves from cultures (Table S3). Considering that different  
208 levels of background human DNA could potentially affect sensitivity, the performance of  
209 NTS was tested using healthy human blood spiked with varied concentrations of the mock  
210 community. NTS detected each species at all six pathogen densities, and the least abundant  
211 fungi and bacteria, with 25 colony-forming units (CFU) in a community of 1000 CFU, were  
212 consistently detected in 12 repeats (Fig. 2A, B). Therefore, the limit of detection was  
213 determined to be 25 CFU in 12/12 positive replicates (Table S5).

214 To determine a proper sequencing time (corresponding to sequencing data) that is required for  
215 confident detection of different amounts of microbes in community, a sequencing library  
216 contained that 48 samples was sequenced on a chip for 12 h. The most abundant bacteria or  
217 fungi, accounting for 30% of the mock community, were detected in all 12 repeats using total  
218 400,000 sequencing reads, which required approximately 30 min. Meanwhile the least  
219 abundant bacteria or fungi, accounting for 5% of the mock community, were identified using  
220 total 2,000,000 reads, which required approximately 4 h (Fig. 2C, D). This indicated that 4 h  
221 sequencing was enough for detection of all pathogens and that a sequencing library with

222 fewer samples could reduce the sequencing time. Considering the diversity of clinical samples,  
223 in which pathogens may account for >30% or <5% of the microbial community, the pathogen  
224 detection time can be achieved <30-minute or require > 4 h of sequencing time.

225

## 226 COMPARISON OF NTS AND CULTURE METHOD IN CLINICAL PRACTICE

227 Upon verification of the performance of NTS using the mock community, 1312 clinical  
228 specimens from 1257 patients were parallelly analyzed by NTS and culture, including 301  
229 and 1011 specimens from sterile (low commensal microbes background) and non-sterile  
230 settings (high commensal microbes background), respectively.

231 Using the culture-based results as a reference, among 289 culture-positive cases, NTS  
232 detected pathogens in 97.58% cases ( $n = 282/289$ ), including identical findings to culture  
233 results in 52.94% cases ( $n = 153/289$ ), detection of additional potential pathogens other than  
234 the culture results in 30.44% of cases ( $n = 88/289$ ), different species of same genus detected  
235 between NTS and culture (6.92%,  $n = 20/289$ ) and different pathogens detected between two  
236 methods (7.27%,  $n = 21/289$ ) (Fig. 3A). Considering the different growth rates of bacteria and  
237 fungi, 84 of the 88 cases of additional pathogens detected by NTS were diagnosed as bacterial  
238 or fungal infections only by culture methods, in which additional critical pathogens ( $n = 2$ ),  
239 additional opportunistic fungi or bacteria ( $n = 67$ ), and potential coinfection with  
240 opportunistic fungi and bacteria ( $n = 19$ ) were detected (Fig. 3A). The NPV of NTS (culture  
241 as reference) was 98.88%, which indicated that NTS was able to detect most of the pathogens  
242 identified by culture (Table 1). The pathogens detected by culture methods were missed by  
243 NTS in 2.42% cases ( $n = 7/289$ ), in which high background of commensal microbes may  
244 impact the detection of pathogen with low abundance.

245 Of the 1023 specimens identified as culture-negative, potential pathogens were detected in  
246 39.78% cases (n = 407/1023) by NTS, especially including 63 critical pathogens (Fig. 3A). In  
247 order to evaluate the accuracy of the NTS results of these cases, GeneXpert (a Food and Drug  
248 Administration-approved assay based on specific PCR of *rpoB* in MTB) analysis was  
249 conducted in 27/34 MTB-positive patients determined by NTS, and 100% concordance was  
250 observed; the other 7 patients were confirmed by acid-fast staining (n = 2) or transferred to a  
251 specialized hospital according to the clinical symptoms without further confirmation (n = 5)  
252 (Table S6).

253 According to the clinical diagnosis record around the time of the parallel NTS and culture test,  
254 1005/1257 patients were diagnosed or suspected as infection by clinicians according to the  
255 clinical symptoms and/or positive results of other clinical tests. However, culture only  
256 reported 289 positive cases, which indicated that several pathogens could have been missed  
257 and could not to be a reference for comprehensive assess of NTS. Thus, clinical diagnosis was  
258 used to evaluate the performance of NTS in infection diagnosis and practicability in clinical  
259 application. The sensitivity of NTS (diagnose as reference) were 58.7% (n = 590/1005),  
260 which was >36% higher than that for culture-based methods (22.1%, n = 222/1005,  $P < 0.01$ ),  
261 and 52 more potential coinfections with bacteria and fungi were detected by NTS (Table 1).  
262 For slow-growing, fastidious pathogens, NTS exhibited a significantly higher positive  
263 detection rate compared to that of culture methods, particularly for MTB (34 vs. 4),  
264 *Aspergillus* (80 vs. 20), *Pneumocystis jirovecii* (20 vs. 0), and *Nocardia* (9 vs. 3) (Table 1).  
265 Moreover, considering the antibiotic pre-exposure in nearly all patients from the Departments  
266 of Respiration and Neurology, no colonies, including fast-growing oral flora and colonizers,  
267 grew after a 72-h incubation period in 44/401 and 55/62 specimens, among which NTS  
268 showed 40.9% (n = 18/44) and 21.0% (n = 12/55) positive results. In those NTS-positive  
269 samples, 11/18 (61.1%) and 10/12 (83.3%) were culturable pathogens, such as *Streptococcus*

270 *aureus* (Table S7).

271 Specimen volume, types of pathogens, abundance of colonizing microorganisms, and  
272 concentration of human DNA backgrounds in different clinical specimens existed to a large  
273 diversity. To assess the impact of different types of specimens on the efficiency of NTS  
274 testing, we evaluated the sensitivity of NTS in different specimens. The positive rate of NTS  
275 was higher than that of culture methods, particularly in the aqueous humor, which usually has  
276 limited specimen volume (60.0% vs. 10.0%,  $P < 0.05$ ), and bronchoalveolar lavage fluid  
277 (BALF), which usually contains high abundance of commensal microbes (56.4% vs. 14.8%,  $P$   
278  $< 0.05$ ), except for superficial secretions ( $P = 0.08$ ) in which the main pathogens were fast-  
279 growing bacteria, such as *Streptococcus aureus* (Fig. 3B). These results indicated that  
280 detection sensitivity of NTS was less impacted by the type of specimen and that NTS was  
281 suitable for the infection detection of various specimens.

282 For all specimens, considering the complexity of clinical samples and more sequencing data  
283 may improve sensitivity, the default total sequencing time was defined as 8 h; the time from  
284 sample collection to the generation of the pathogen report was within 24 h for NTS ( $n = 1312$ ),  
285 which was significantly shorter than the estimated median time of 72 h for culture methods ( $P$   
286  $< 0.001$ ) (Fig. 4). Notably, real-time information was generated during sequencing, and a pre-  
287 report can be obtained if the data meet the positive criteria, further reducing the turnaround  
288 time. Briefly, in many emergency cases, 10 min sequencing data was sufficient to identify the  
289 pathogens and targeted antibiotics can be administrated by clinicians on the same day of  
290 detection without waiting for the completion of an 8 h sequencing.

## 291 EFFECT OF NTS ON ANTIBIOTIC MANAGEMENT

292 To assess the impact of pathogen detection by NTS on antibiotic management, we  
293 investigated the patients' electronic records. Empirical antimicrobial agents were initiated

294 before NTS in 93.9% (31/33) of NTS-positive samples in the Department of Respiratory ICU.  
295 Based on the NTS results, 51.52% (17/33) of patients were switched to targeted antibiotics (n  
296 = 7) or different antibiotics covering the same antibacterial spectrum (n = 10). NTS results did  
297 not trigger modification of antibiotic therapy in 42.42% (14/33) of patients; among these  
298 patients, 85.71% (12/14) maintained the original anti-infection regimen, which already  
299 covered the pathogen detected by NTS, and 14.29% (2/14) were discharged from hospital  
300 without subsequent therapy (Table S8). Four patients were evaluated by continuous NTS  
301 assay during the treatment process. In four cases, the pathogens detected in the first NTS  
302 assay and triggering antibiotic modification were eliminated according to the results of the  
303 second NTS assay, resulting in the suspension or de-escalation of targeted antibiotics. In one  
304 case, other pathogen were detected in the second NTS, which may have been transient  
305 colonizers with the potential to induce a nosocomial infection (Table 2).

306

## 307 **Discussion**

308 We developed and examined the performance and clinical impact of targeted full-length  
309 amplicon sequencing in clinical practice, in a setting where most patients have negative  
310 culture results (8). NTS increased the sensitivity of pathogen detection for patients with  
311 diagnosed or suspected infection and detected more causative pathogens in patients with a risk  
312 of infection. These findings are consistent with those of previous sequencing-based studies (6,  
313 8, 30, 31). Compared to culture methods, the detection rate by NTS was higher for nearly all  
314 specimen types, particularly in the cerebrospinal fluid (CSF) and aqueous humor. Moreover,  
315 slow-growing, uncultivable pathogens were detected in a single NTS test, particularly fungi  
316 and MTB (32). For infections induced by culturable bacteria, NTS was less impacted by pre-  
317 antibiotic exposure and more effectively detected coinfections. Potential pathogens were  
318 detected in specimens with no clone growth in culture. Continuous NTS helped clinicians

319 determine effective treatments, suspend, or de-escalate the use of targeted drugs, and monitor  
320 the risk of secondary or nosocomial infections.

321 By NTS, a turnaround time of <24 h can be achieved for all specimens. Given its high NPV  
322 using culture results for reference, a negative result or non-bacterial etiology can lead to de-  
323 escalation or even the discontinuation of antimicrobial therapy (33). Moreover, a 6-h  
324 diagnostic pre-report can be issued if diagnostic thresholds are met. We encountered  
325 emergency cases for which this pre-report substantially improved the diagnosis and care. We  
326 identified *Nocardia farcinica*, which is rare in China, in a patient with an emergency  
327 intracranial infection, and extremely fast-growing pathogens in the tissue of a patient with  
328 Paget's disease. In addition, NTS detection of fungi and rare coinfections of fungi with  
329 symbiotic bacteria, often neglected by routine clinical diagnosis, is possible.

330 Our results clearly support the combination of targeted amplification and nanopore  
331 sequencing; however, amplification may alter the flora structure, affecting the detection of  
332 pathogens with ultralow abundance. A total of 80% of NTS false-negative samples were  
333 derived from the respiratory tract, suggesting that the extremely high proportion of  
334 commensal colonizers by improper sample procurement impacted the sensitivity of NTS.  
335 NTS amplification requires adjustment depending on the specimen type. Importantly, many  
336 potentially pathogenic bacteria, such as *Pseudomonas* and *Streptococcus*, are ubiquitous (27),  
337 and their abundance must be contextualized by cohort-specific norms.

338 This study had several limitations. First, it was conducted at a single central hospital, and the  
339 number of specimens varied substantially among departments. Further studies at hospitals  
340 with different patient populations and medical practices are needed. Second, unmeasured  
341 factors may have influenced decision-making. In addition, we cannot measure the impact of  
342 NTS on patient outcomes beyond antibiotic selection. Finally, given the retrospective nature  
343 of the study, all available tests were not performed on all samples, and we did not  
344 systematically compare NTS results to those of other molecular diagnostic methods. Future

345 studies should focus on the impact of NTS on patient-centered outcomes (i.e., length of stay  
346 and mortality), antibiotic stewardship, and cost compared to a wider range of methods.

347 In conclusion, the NTS approach developed in this study enabled simultaneous detection and  
348 same-day reporting of a myriad of bacteria and fungi in specimens with practical operability  
349 in clinical settings. This approach fills the gap between highly targeted PCR-based diagnostic  
350 methods and resource-intensive sequencing-based metagenomics methods. The equipment  
351 required for NTS testing is small and portable; therefore, NTS can be directly performed in  
352 various hospitals or clinics, without sending specimens to large sequencing institutions or  
353 third parties detection institutions. NTS is recommended for monitoring severe patients during  
354 treatment because of its accuracy, comprehensiveness, and rapidity.

355

#### 356 **Conflicts of interest**

357 Wuhan Dgensee Clinical Laboratory Co., Ltd applied patents based on this novel technology.

358

#### 359 **Reference**


- 360 1. Yang CC, Sy CL, Huang YC, Shie SS, Shu JC, Hsieh PH, et al. Risk factors of treatment  
361 failure and 30-day mortality in patients with bacteremia due to mrsa with reduced  
362 vancomycin susceptibility. *Sci Rep* 2018;8:7868.
- 363 2. Laxminarayan R, Matsoso P, Pant S, Brower C, Rottingen JA, Klugman K, Davies S.  
364 Access to effective antimicrobials: A worldwide challenge. *Lancet* 2016;387:168-75.
- 365 3. Wilson MR, O'Donovan BD, Gelfand JM, Sample HA, Chow FC, Betjemann JP, et al.  
366 Chronic meningitis investigated via metagenomic next-generation sequencing. *JAMA*  
367 *Neurol* 2018;75:947-55.
- 368 4. Simner PJ, Miller S, Carroll KC. Understanding the promises and hurdles of metagenomic  
369 next-generation sequencing as a diagnostic tool for infectious diseases. *Clin Infect Dis*  
370 2018;66:778-88.
- 371 5. Ivy MI, Thoendel MJ, Jeraldo PR, Greenwood-Quaintance KE, Hanssen AD, Abdel MP, et  
372 al. Direct detection and identification of prosthetic joint infection pathogens in  
373 synovial fluid by metagenomic shotgun sequencing. *J Clin Microbiol* 2018;56.
- 374 6. Langelier C, Kalantar KL, Moazed F, Wilson MR, Crawford ED, Deiss T, et al. Integrating  
375 host response and unbiased microbe detection for lower respiratory tract infection  
376 diagnosis in critically ill adults. *P Natl Acad Sci USA* 2018;115:E12353-E62.
- 377 7. Langelier C, Zinter MS, Kalantar K, Yanik GA, Christenson S, O'Donovan B, et al.  
378 Metagenomic sequencing detects respiratory pathogens in hematopoietic cellular  
379 transplant patients. *Am J Respir Crit Care Med* 2018;197:524-8.



- 380 8. Basein T, Gardiner BJ, Andujar Vazquez GM, Joel Chandranesan AS, Rabson AR, Doron  
381 S, Snyderman DR. Microbial identification using DNA target amplification and  
382 sequencing: Clinical utility and impact on patient management. *Open Forum Infect Di*  
383 *2018;5:ofy257*.
- 384 9. Clarke EL, Lauder AP, Hofstaedter CE, Hwang Y, Fitzgerald AS, Imai I, et al. Microbial  
385 lineages in sarcoidosis. A metagenomic analysis tailored for low-microbial content  
386 samples. *Am J Respir Crit Care Med* 2018;197:225-34.
- 387 10. Guet-Revillet H, Jais JP, Ungeheuer MN, Coignard-Biehler H, Duchatelet S, Delage M, et  
388 al. The microbiological landscape of anaerobic infections in hidradenitis suppurativa:  
389 A prospective metagenomic study. *Clin Infect Dis* 2017;65:282-91.
- 390 11. Simner PJ, Miller HB, Breitwieser FP, Pinilla Monsalve G, Pardo CA, Salzberg SL, et al.  
391 Development and optimization of metagenomic next-generation sequencing methods  
392 for cerebrospinal fluid diagnostics. *J Clin Microbiol* 2018;56.
- 393 12. Stefan CP, Hall AT, Minogue TD. Detection of 16s rna and kpc genes from complex  
394 matrix utilizing a molecular inversion probe assay for next-generation sequencing. *Sci*  
395 *Rep* 2018;8:2028.
- 396 13. Shendure J, Balasubramanian S, Church GM, Gilbert W, Rogers J, Schloss JA, Waterston  
397 RH. DNA sequencing at 40: Past, present and future. *Nature* 2017;550:345-53.
- 398 14. Goodwin S, McPherson JD, McCombie WR. Coming of age: Ten years of next-generation  
399 sequencing technologies. *Nat Rev Genet* 2016;17:333-51.
- 400 15. New research algorithms yield accuracy gains for nanopore sequencing.  
401 [https://nanoporetech.com/about-us/news/new-research-algorithms-yield-accuracy-](https://nanoporetech.com/about-us/news/new-research-algorithms-yield-accuracy-gains-nanopore-sequencing)  
402 [gains-nanopore-sequencing](https://nanoporetech.com/about-us/news/new-research-algorithms-yield-accuracy-gains-nanopore-sequencing)
- 403 16. Deamer D, Akeson M, Branton D. Three decades of nanopore sequencing. *Nat Biotechnol*  
404 *2016;34:518-24*.
- 405 17. Petersen LM, Martin IW, Moschetti WE, Kershaw CM, Tsongalis GJ. Third-generation  
406 sequencing in the clinical laboratory: Exploring the advantages and challenges of  
407 nanopore sequencing. *J Clin Microbiol* 2019;58.
- 408 18. Kono N, Arakawa K. Nanopore sequencing: Review of potential applications in functional  
409 genomics. *Dev Growth Differ* 2019;61:316-26.
- 410 19. Branton D, Deamer DW, Marziali A, Bayley H, Benner SA, Butler T, et al. The potential  
411 and challenges of nanopore sequencing. *Nat Biotechnol* 2008;26:1146-53.
- 412 20. Votintseva AA, Bradley P, Pankhurst L, Del Ojo Elias C, Loose M, Nilgiriwala K, et al.  
413 Same-day diagnostic and surveillance data for tuberculosis via whole-genome  
414 sequencing of direct respiratory samples. *J Clin Microbiol* 2017;55:1285-98.
- 415 21. Charalampous T, Kay GL, Richardson H, Aydin A, Baldan R, Jeanes C, et al. Nanopore  
416 metagenomics enables rapid clinical diagnosis of bacterial lower respiratory infection.  
417 *Nature biotechnol* 2019;37:783-92.
- 418 22. Yang L, Haidar G, Zia H, Nettles R, Qin S, Wang X, et al. Metagenomic identification of  
419 severe pneumonia pathogens in mechanically-ventilated patients: A feasibility and  
420 clinical validity study. *Respir Res* 2019;20:265.
- 421 23. Moon J, Jang Y, Kim N, Park WB, Park KI, Lee ST, et al. Diagnosis of haemophilus  
422 influenzae pneumonia by nanopore 16s amplicon sequencing of sputum. *Emerging*  
423 *Infect Dis* 2018;24:1944-6.
- 424 24. Moon J, Kim N, Lee HS, Shin HR, Lee ST, Jung KH, et al. *Campylobacter fetus*  
425 meningitis confirmed by a 16s rna gene analysis using the minion nanopore  
426 sequencer, south korea, 2016. *Emerg Microbes Infect* 2017;6:e94.
- 427 25. D'Andreano S, Cuscó A, Francino O. Rapid and real-time identification of fungi up to the  
428 species level with long amplicon nanopore sequencing from clinical samples. *bioRxiv*  
429 *2020:2020.02.06.936708*.




- 430 26. Dickson RP, Erb-Downward JR, Prescott HC, Martinez FJ, Curtis JL, Lama VN,  
431 Huffnagle GB. Analysis of culture-dependent versus culture-independent techniques  
432 for identification of bacteria in clinically obtained bronchoalveolar lavage fluid. *J Clin*  
433 *Microbiol* 2014;52:3605-13.
- 434 27. Zinter MS, Dvorak CC, Mayday MY, Iwanaga K, Ly NP, McGarry ME, et al. Pulmonary  
435 metagenomic sequencing suggests missed infections in immunocompromised children.  
436 *Clin Infect Dis* 2018.
- 437 28. Miao Q, Ma Y, Wang Q, Pan J, Zhang Y, Jin W, et al. Microbiological diagnostic  
438 performance of metagenomic next-generation sequencing when applied to clinical  
439 practice. *Clin Infect Dis* 2018;67:S231-S40.
- 440 29. Kim BJ, Lee SH, Lyu MA, Kim SJ, Bai GH, Chae GT, et al. Identification of  
441 mycobacterial species by comparative sequence analysis of the rna polymerase gene  
442 (rpoB). *J Clin Microbiol* 1999;37:1714-20.
- 443 30. Gomez CA, Budvytiene I, Zemek AJ, Banaei N. Performance of targeted fungal  
444 sequencing for culture-independent diagnosis of invasive fungal disease. *Clin Infect*  
445 *Dis* 2017;65:2035-41.
- 446 31. Cherkaoui A, Emonet S, Ceroni D, Candolfi B, Hibbs J, Francois P, Schrenzel J.  
447 Development and validation of a modified broad-range 16s rDNA PCR for diagnostic  
448 purposes in clinical microbiology. *J Microbiol Meth* 2009;79:227-31.
- 449 32. Rampini SK, Bloemberg GV, Keller PM, Buchler AC, Dollenmaier G, Speck RF, Bottger  
450 EC. Broad-range 16s rRNA gene polymerase chain reaction for diagnosis of culture-  
451 negative bacterial infections. *Clin Infect Dis* 2011;53:1245-51.
- 452 33. Parize P, Muth E, Richaud C, Gratigny M, Pilimis B, Lamamy A, et al. Untargeted next-  
453 generation sequencing-based first-line diagnosis of infection in immunocompromised  
454 adults: A multicentre, blinded, prospective study. *Clin Microbiol Infect* 2017;23:574  
455 e1- e6.  
456



457

458 **Fig. 1.** Design of NTS for simultaneous detection of bacterial and fungal infection. Three marker gene databases, corresponding to 16s rRNA,  
 459 ITS1/2, and *rpoB*, were constructed from the sequences from the NCBI database. The results of multiplex sequence alignment of each database was  
 460 used to analyze the conservative region and degeneration of each marker gene base. The blue primers were used in previous studies and selected as  
 461 “start primers” for the design of other “additional primers” which is labeled by other colors. The red vertical bar on the primer indicates degenerate  
 462 base. The “start primers” and “additional primers” for each marker gene was mixed at the molar ratio of 3:1. The mixed primers were then used to  
 463 amplify the marker gene, individually. The PCR products of the 16s rRNA, ITS1/2, and *rpoB* from the same sample were then pooled at a mass  
 464 ratio of 10:3:1. This pooled product was used for library preparation, nanopore sequencing and bioinformatic analysis.




465

466 **Fig. 2.** Proficiency test of NTS with a mock community. Detection of the least abundant  
467 bacteria (A) and fungi (B) in the mock community. *Moraxella catarrhalis* and *Candida*  
468 *tropicalis* each accounted for 5% of the mock community. Three different densities from 25  
469 to 150 CFU/mL were tested with 12 repeats. Each spot represents a repeat detection. (C)  
470 Comparison of the RPM of each strain in the mock community in a saline background with  
471 that in human blood. The correlation between the detection of bacteria (C) and fungi (D) with  
472 sequencing data used for the analysis. Dashed line indicates the positive threshold between  
473 the sample and control used as the limit of detection for pathogens in this study.  
474 Abbreviations: NTS, nanopore targeted sequencing; CFU, colony-forming units; RPM,  
475 aligned reads of per million sequence reads.

476


477



478  
 479 **Fig. 3.** Comparison of NTS and culture method in real clinical practice. (A) Evaluation of  
 480 concordance between NTS and culture results. Detected microbes were defined as critical or  
 481 opportunistic bacteria or fungi according to previous studies and clinical guidelines. (B)  
 482 Positive rates of NTS for each kind of specimen compared to that of culture results using the  
 483 clinical diagnosis of each patient as reference. Abbreviations: NTS, nanopore targeted  
 484 sequencing; BALF, bronchoalveolar lavage fluid; CSF, cerebrospinal fluid.

485

Timeline of NTS in real clinical practice



486

487

488 **Fig. 4.** Schematic illustration of the total duration of NTS in clinical practice, including  
489 pretreatment, DNA extraction, targeted amplification and library construction, sequencing,  
490 bioinformatic analysis, and generation of the real-time report.

491

492 **Table 1. Diagnostic Performance of NTS and Culture**

	<b>Culture</b>	<b>NTS</b>	<b>P value</b>
<b>Diagnostic performance according to clinical diagnosis</b>			
Sensitivity refer to clinical diagnosis	22.09%, 222/1005	58.71%, 590/1005	< .01
<b>Diagnostic performance according to culture diagnosis</b>			
Sensitivity refer to culture	-	97.57%, (282+7)	282/ -
Specificity refer to culture	-	60.21%, (616+407)	616/ -
PPV refer to culture	-	40.92%, (282+407)	282/ -
NPV refer to culture	-	98.87%, (616+7)	616/ -
<b>Detection of different pathogens</b>			
Coinfection of bacteria and fungi	8	60	< .01
MTB	4, 4/4 detected by NTS	34	< .01
<i>Cryptococcus</i>	2, 2/2 detected by NTS	9	ns
<i>Streptococcus aureus</i>	28, 28/28 detected by NTS	58	< .01
<i>Escherichia coli</i>	33, 31/33 detected by NTS	68	< .01
<i>Klebsiella pneumoniae</i>	22, 20/22 detected by NTS	44	< .01
<i>Enterococcus</i>	31, 23/31 identical and 7/31 with different species detected by NTS	91	< .05
<i>Acinetobacter baumannii</i>	54, 51/54 detected by NTS	91	< .05
<i>Haemophilus influenzae</i>	3, 3/3 detected by NTS	53	< .01
<i>Candida</i>	27, 27/27 detected by NTS	160	< .01
<i>Nocardia</i>	3, 3/3 detected by NTS	9	< .01
<i>Aspergillus</i>	20, 15/20 detected by NTS	80	< .01
<i>Pneumocystis jirovecii</i>	0	20	< .01
<i>Bordetella</i>	0	3	< .01
<i>Legionella</i>	0	2	< .01
<i>Tropheryma whipplei</i>	0	5	< .01
NTM	0	3	< .01
<i>Mycoplasma pneumoniae</i>	0	59	< .01
<i>Ureaplasma</i>	0	10	< .01

---

	<i>Gardnerella vaginalis</i>	0	20	< .01
--	------------------------------	---	----	-------

---

493

494 Abbreviation: NTS, nanopore targeted sequencing; MTB, *Mycobacterium tuberculosis*; NTM,

495 *Nontuberculous mycobacteria*; PPV, positive predicted value; NPV, negative predicted values.

496 **Table 2. Continuous NTS assay during the treatment process**

Patient number	Test times	Culture Result	NTS Result	Clinical Diagnosis	Antibiotics and Therapeutic Effect
PT.35	1st assay	Negative	<i>Pneumocystis jirovecii</i> CO: <i>Staphylococcus epidermidis</i>	Severe pneumonia	1. (Antibiotics before 1 <sup>st</sup> NTS) cefoperazone, ganciclovir, moxifloxacin, and then imipenem, voriconazole, sulfonamide 2. (Therapeutic effect before 1 <sup>st</sup> NTS) the patient's condition worsened
	2nd assay	Negative	CO: <i>Staphylococcus haemolyticus</i>		3. (Antibiotics after 1 <sup>st</sup> NTS) sulfonamide 4. (Therapeutic effect after 2 <sup>nd</sup> NTS) Discharged
PT.26	1st assay	<i>Klebsiella pneumoniae</i>	OP: <i>Klebsiella pneumoniae</i> CO: <i>Streptococcus mitis</i>	Neonatal respiratory infection	1. (Antibiotics before 1 <sup>st</sup> NTS) imipenem, linezolid, cefotiam, and cefoperazone 2. (Therapeutic effect before 1 <sup>st</sup> NTS) The index of infection was significantly increased
	2nd assay	Negative	CO: <i>Enterococcus faecalis</i>		3. (Antibiotics after 1 <sup>st</sup> NTS) cefoperazone discontinuation and meropenem treatment 4. (Therapeutic effect after 2 <sup>nd</sup> NTS) Discharged
PT.48	1st assay	<i>Aspergillus</i>	OP: <i>Aspergillus</i>	Severe pneumonia	1. (Antibiotics before 1 <sup>st</sup> NTS) imipenem, voriconazole 2. (Antibiotics after 1 <sup>st</sup> NTS) voriconazole was discontinued and caspofungin was administrated
	2nd assay	Negative	Negative		3. (Therapeutic effect after 2 <sup>nd</sup> NTS) The patient's lung infection was better than before according to CT



PT.11	1st assay	Negative	OP: <i>Streptococcus pneumoniae</i> CO: <i>Neisseria flavus</i> , <i>Gemella sanguinis</i>	Community pneumonia acquired	1. (Antibiotics before 1 <sup>st</sup> NTS) routine anti-infective treatment
	2nd assay	<i>Acinetobacter baumannii</i>	OP: <i>Acinetobacter baumannii</i> Candida albicans		2. (Antibiotics after 1 <sup>st</sup> NTS) Considering pneumonia of <i>streptococcus pneumoniae</i> and the current anti-infective treatment regimen was continued 3. (Therapeutic effect After 1 <sup>st</sup> NTS) Indexs of infection decreased, but there was still a high fever at night. 4. (Antibiotics after 2 <sup>nd</sup> NTS) Imipenem cisastatin and micafungin 5. (Therapeutic effect After 2 <sup>nd</sup> NTS) Discharged

497

498

499

500

---

Abbreviation : NTS, nanopore targeted sequencing; OP, opportunistic pathogens; CO, commensal bacteria/fungi